Veröffentlichungsdatum: 6 Dezember 2018
Projektträger – zwischengeschaltetes Finanzinstitut
MARINOMED BIOTECH AG
The company is a biopharmaceutical company developing therapeutic solutions for the treatment of respiratory and ophthalmic conditions. The eligible investment plan includes research and development (R&D) and related expenses to finance the development of the company's two proprietary biotechnology platforms during the investment period 2019-2022.
The proposed transaction will support R&D investments that are required in order to further advance the promoter's product pipeline and bring the products to market.
- Dienstleistungen - Erbringung von Freiberuflichen, Wissenschaftlichen und Technischen Dienstleistungen
Vorgeschlagene EIB-Finanzierung (voraussichtlicher Betrag)
EUR 15 million
Gesamtkosten (voraussichtlicher Betrag)
EUR 37 million
The project mainly concerns investments in R&D that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an environmental impact assessment (EIA) under the Directive 2011/92/EU. Full environmental details will be verified during the appraisal.
The promoter is a private company not operating in the utilities sector and not having the status of a contracting authority. Thus, it is not covered by EU Directives on procurement. However, the promoter's procurement procedures are expected to be in line with EIB guidelines for private sector projects. The Bank's services will verify details during the project due diligence.
Unterzeichnet - 25/02/2019
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The data provided on this page is therefore indicative and cannot be considered to represent official EIB policy (see also the Explanatory notes).